Allergy-relieving Eye Drops Market - Snapshot

The global allergy-relieving eye drops market is expected to reach a value of US$ 1,930.3 Mn by the end of 2026, expanding at a significant CAGR of 5.0% during the forecast period. Increase in prevalence and incidence rates of eye-related disorders, high unmet needs in patients with ocular allergy, increased geriatric population, raised awareness about eye diseases in developing countries are expected to boost the allergy-relieving eye drops market during the forecast period. Moreover, significant rise in incidence of eye-related diseases, especially in developed countries, is anticipated to drive the allergy-relieving eye drops market between 2018 and 2026. According to the Prevent Blindness Report, the number of people in the U.S. suffering from cataract is expected to increase from 24.4 Mn in 2010, to 30.5 Mn by 2020, and the number of people suffering from diabetic retinopathy in the U.S. is projected to rise from 7.7 Mn in 2010 to reach 9.2 Mn by 2020

The global allergy-relieving eye drops market has been segmented based on drug class, type, distribution channel, and region. In terms of drug class, the global market has been classified into antihistamines, non-steroidal anti-inflammatory drugs, vasoconstrictors, and others. The antihistamines segment dominates the allergy-relieving eye drops market, in terms of value. The wide acceptance of antihistamines as the first line of treatment for allergic conjunctivitis is likely to drive the segment. Furthermore, increase in the prevalence of allergic conjunctivitis and rise in awareness about eye-related disorders are anticipated to propel the segment during the forecast period. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of ocular allergy. The vasoconstrictors segment follows the antihistamines segment, in terms of share, of the global allergy-relieving eye drops market. The dominance of the segment is attributed to the extensive utilization of vasoconstrictors to relieve redness of the eyes associated with ocular allergy.

allergy-relieving-eye-drops-market.jpg

In terms of type, the global market has been classified into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, and others. The seasonal and perennial allergic conjunctivitis segment is likely to dominate the global allergy-relieving eye drops market during the forecast period.

In terms of distribution channel, the allergy-relieving eye drops market has been segregated into hospital pharmacies, retail, and online sales. The retail segment held a major share of the market in 2017, followed by hospital pharmacies. The retail segment is expected to maintain its market share during forecast period due to the availability of both prescription as well as OTC drugs for allergic conjunctivitis. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for certain form of ocular allergies.

In terms of region, the allergy-relieving eye drops market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the allergy-relieving eye drops market, owing to the high awareness about minor eye-related disorders in the U.S. and increased prevalence of allergic conjunctivitis in the region. Moreover, North America is anticipated to be a highly attractive market for allergy-relieving eye drops during the forecast period, owing to the high cost of prescription drugs and a significant number of people in this region covered by medical insurance.

Major players operating in the allergy-relieving eye drops market include Allergan Plc., Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical companies, which is expected to increase the product availability and thereby boost the market.

Allergy-relieving Eye Drops Market: Overview

This report analyzes the current and future scenario of the global allergy-relieving eye drops market for the period 2018 to 2026. Rise in geriatric population, increased prevalence of ocular disorders, and high unmet medical needs are likely to be major drivers of the global allergy-relieving eye drops market during the forecast period.

The allergy-relieving eye drops market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, type, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the allergy-relieving eye drops market.

Allergy-relieving Eye Drops Market: Key Segments

Based on drug class, the global allergy-relieving eye drops market has been segmented into antihistamines, non-steroidal anti-inflammatory drugs, vasoconstrictors, and others. The segments have been analyzed based on available drugs used for the treatment of allergic conjunctivitis. Based on type, the market has been classified into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, and others. In terms of distribution channel, the global allergy-relieving eye drops market has been divided into hospital pharmacies, retail, and online sales. Based on market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Allergy-relieving Eye Drops Market: Regional Outlook

In terms of region, the global allergy-relieving eye drops market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global allergy-relieving eye drops market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Allergan Plc., Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.

The global allergy-relieving eye drops market has been segmented as below:

Drug Class

  • Antihistamines
  • Non-steroidal anti-Inflammatory Drugs
  • Vasoconstrictors
  • Others

Type

  • Seasonal and Perennial Allergic Conjunctivitis
  • Vernal Keratoconjunctivitis
  • Atopic Keratoconjunctivitis
  • Giant Papillary Conjunctivitis
  • Others

Distribution Channel

 

  • Hospital Pharmacies
  • Retail
  • Online Sales

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa